viewTiziana Life Sciences PLC

Tiziana Life Sciences stem cell tool superior to market leader Exact Sciences' Oncotype DX in breast cancer head to head

The potential of the group's StemPrintER will be underlined in a poster presentation

Tiziana Life Sciences PLC -

Tiziana Life Sciences PLC (LON:TILS, NASDAQ:TLSA) has said that two poster presentations at a top medical conference underline the potential of its technology in predicting the recurrence of breast cancer.

The group's StemPrintER stem cell-based genomic prognostic tool showed superiority over the market leader, Oncotype DX, developed by Exact Sciences (NASDAQ:EXAS), when it came to predicting the recurrence of the disease in ER+/HER2- postmenopausal patients. 

More than 800 women took part in the study to be presented at a session of the American Society of Clinical Oncology (ASCO) virtual conference starting later on Friday.

A second poster describing results of the prediction of distant recurrence using a next-generation StemPrintER model, named SPARE, showed even more refined accuracy than standard markers.

Both submissions were authored by a team of scientists from the European Institute of Oncology in Milan. The head-to-head comparison of StemPrintER with Oncotype DX was conducted in collaboration with the Royal Marsden Hospital and Queen Mary University in London.

Last week Tiziana announced plans to spin out its StemPrintER and SPARE genomics-based personalised medicine businesses as a separate stock market quoted company.

This will allow the newly independent group to secure independent funding to accelerate the accelerated development of the StemPrintER genomic test, the group said. It will also ensure the demerged entity can focus solely on the personalised medicines market.

Major highlights from the ASCO posters:

The first poster, which was also part of a discussion session, shows that StemPrintER:

  • Outperforms Oncotype DX in 10-year risk prediction in more than 800 ER+/HER2- postmenopausal breast cancer patients in the analysis, including in lymph node-negative (N0) and 1 to 3 lymph node-positive (N1-3) patients
  •  Significantly stratifies high vs. low-risk groups when adjusted for clinical parameters as expressed by clinical treatment scores (CTS)

The second poster reveals:

  • Around 20% superiority to the traditional clinicopathological parameters, as expressed by the CTS, in providing prognostic information for the more than 1,800 patients analysed and in certain populations was demonstrated to be up to 40-50% more accurate
  • Investigators found that SPARE added substantial prognostic information to CTS, but the inverse was not proven to be the case

For more information click here 

Quick facts: Tiziana Life Sciences PLC

Price: 112.5 GBX

Market: AIM
Market Cap: £187.21 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tiziana Life Sciences PLC named herein, including the promotion by the Company of Tiziana Life Sciences PLC in any Content on the Site, the...



Tiziana Life Sciences to fast track development of its coronavirus antibody...

Tiziana Life Sciences (LON:TILS)(NASDAQ:TLSA) CEO Dr Kunwar Shailubhai tells Proactive London's Andrew Scott they're accelerating a potential treatment for COVID-19 alongside a unique method of delivering the inhaled version of the drug. As part of the fast-track process, he says the company...

1 week, 4 days ago

2 min read